Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
EVGN
Evogene Ltd.
Biomica's microbiome therapeutics program (BMC128) targets human health, fitting Immunology Therapeutics within Biotech.
|
$8.56M |
$1.25
-1.19%
|
|
BLRX
BioLineRx Ltd.
BioLineRx's lead oncology asset motixafortide (APHEXDA) places the company squarely in oncology with an approved stem cell mobilization therapy and ongoing cancer indications development.
|
$8.32M |
$3.43
-1.15%
|
|
CBIO
Crescent Biopharma, Inc.
Crescent Biopharma focuses on oncology therapeutics, explicitly mentioning next-gen cancer biologics and its lead PD-1 x VEGF bispecific and ADCs.
|
$8.23M |
$12.25
-3.92%
|
|
TSBX
Turnstone Biologics Corp.
Company's core business is oncology-focused biotechnology, including immunotherapy approaches (TIL-based strategies) in solid tumors.
|
$8.21M |
$0.35
|
|
CELZ
Creative Medical Technology Holdings, Inc.
CELZ develops autologous/allogeneic cell therapies (ImmCelz and AlloStem), a core cell therapy business.
|
$8.20M |
$3.07
-3.15%
|
|
SBFM
Sunshine Biopharma, Inc.
SBFM's Nora Pharma operates a growing Canadian generic prescription drug business.
|
$8.06M |
$1.67
-5.65%
|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$7.88M |
$1.43
-1.04%
|
|
BMRA
Biomerica, Inc.
Offers Contract Manufacturing services with notable growth, i.e., contract manufacturing revenue stream.
|
$7.85M |
$2.69
-3.41%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$7.85M |
$3.21
+8.81%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$7.82M |
$1.75
-7.18%
|
|
APRE
Aprea Therapeutics, Inc.
APRE is an oncology-focused biotech developing cancer therapies, namely DDR inhibitors, which aligns with Biotech - Oncology.
|
$7.74M |
$1.41
+0.71%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$7.69M |
$4.71
-8.64%
|
|
TRIB
Trinity Biotech plc
Includes companion diagnostics/biomarker-guided tests as part of its oncology-focused diagnostic portfolio.
|
$7.67M |
$1.01
+1.50%
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$7.63M |
$6.04
+4.77%
|
|
PAVM
PAVmed Inc.
PAVmed's biopharma expansion targets oncology assets, aligning with Biotech - Oncology.
|
$7.56M |
$0.40
-5.99%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaCell's core focus is oncology immunotherapies, aligning with Biotech - Oncology.
|
$7.45M |
$9.82
-10.73%
|
|
ALZN
Alzamend Neuro, Inc.
Company's pipeline includes Alzheimer's disease therapeutics (ALZN002) and a focused strategy on Alzheimer's treatment.
|
$7.33M |
$2.41
-4.74%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$7.25M |
$1.42
+1.07%
|
|
NLSP
NLS Pharmaceutics AG
Kadimastem's allogeneic cell-therapy platform (IsletRx, AstroRx) and NLSP's merger create a clear Cell Therapy business line.
|
$7.19M |
$0.79
-89.59%
|
|
ADXN
Addex Therapeutics Ltd
Addex's core product category is oral small-molecule therapeutics (allosteric modulators including GABAB PAMs and mGluR modulators).
|
$7.17M |
$9.29
+2.03%
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$7.03M |
$2.42
+4.76%
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is a recombinant lipase enzyme produced as a therapeutic for exocrine pancreatic insufficiency, fitting Recombinant Proteins & Enzymes.
|
$6.75M |
$4.12
-3.18%
|
|
DQWS
DSwiss, Inc.
DQWS provides turnkey OEM/ODM contract manufacturing services for health care, beauty, and nutraceutical products.
|
$6.62M |
$0.03
|
|
MBRX
Moleculin Biotech, Inc.
Moleculin Biotech's lead asset Annamycin is a cancer drug candidate, placing the company squarely in the Biotech - Oncology category.
|
$6.57M |
$0.51
+8.70%
|
|
SNOA
Sonoma Pharmaceuticals, Inc.
Eye care products, aligning with ophthalmic drug offerings.
|
$6.47M |
$3.92
-0.51%
|
|
IBO
Impact BioMedical Inc.
Linebacker is an oncology-focused platform of electrophilically enhanced polyphenol compounds licensed for development and commercialization.
|
$6.47M |
$0.53
-1.66%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB's encapsulation technology is a drug-delivery platform enabling localized prodrug activation.
|
$6.38M |
$0.91
-2.15%
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$6.35M |
$1.37
-5.52%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$6.22M |
$5.67
-1.39%
|
|
KTTA
Pasithea Therapeutics Corp.
Pasithea's lead candidate PAS-4.00 is a MEK inhibitor targeting MAPK pathway-driven tumors, aligning with oncology-focused biotech.
|
$6.06M |
$0.82
+1.14%
|
|
ICU
SeaStar Medical Holding Corporation
QUELIMMUNE represents an immunology therapeutic, aligning with Immunology Therapeutics.
|
$6.02M |
$0.55
-3.21%
|
|
CYCN
Cyclerion Therapeutics, Inc.
Cyclerion is centered on neuropsychiatric drug development, specifically an individualized therapy for Treatment Resistant Depression (TRD).
|
$6.00M |
$1.84
-1.34%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$5.93M |
$0.35
-2.87%
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$5.90M |
$1.93
-1.28%
|
Showing page 23 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
